Astellas Pharma Inc. ALPMY
16.41 USD -0.10 (-0.61%)
At closeNov 10, 2026, 4:00 PM EST
16.30 Day range 16.41
11.45 52-week range 17.35
- YTD
- +23.48%
- 1 year
- +43.82%
- Market cap
- 29.43B
- EPS (ttm)
- 1.35
- P/E ratio
- 12.16
- YTD return
- +23.48%
- 1-year return
- +43.82%
- Volume
- 3.14K
- Avg volume
- 97.05K
- Open
- 16.33
- Previous close
- 16.51
- Day's range
- 16.30 – 16.41
- 52-week range
- 11.45 – 17.35
- Earnings date
- Oct 29, 2026
No chart data for this range yet.
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.3912.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.3912 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3363 | 0.503 | +0.17 | +49.57% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1941 | 0.1521 | -0.04 | -21.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2916 | 0.364 | +0.07 | +24.83% |
| Oct 30, 2025 | Sep 30, 2025 | 0.1993 | 0.30 | +0.10 | +50.53% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1356 | 0.40 | +0.26 | +194.99% |
News
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year? 
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year? 
Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis 
Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s What Happened 
Astellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9% 
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer 
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers 
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis 
New Strong Sell Stocks for August 19th 
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors
Your note
Sign in to keep a note on ALPMY — it syncs with the Stock Master app.